CD274 and posterior cortical atrophy: To this end, immunotherapy for PCa has evolved, with PD-1/PD-L1, and Sipuleucel-T, a DC-based autologous cellular immunotherapy, both approved by the FDA and used for treating patients with PCa [249,250,251,252,253,254,255,256,257,258].